-
1دورية أكاديمية
المؤلفون: Roubaud, Guilhem, Özgüroğlu, M., Penel, Nicolas, Matsubara, N., Mehra, N., Kolinsky, M. P., Procopio, G., Feyerabend, S., Joung, J. Y., Gravis, Gwenaelle, Nishimura, K., Gedye, C., Padua, C., Shore, N., Thiery-Vuillemin, Antoine, Saad, F., Van Alphen, R., Carducci, M. A., Desai, C., Brickel, N., Poehlein, C., Del Rosario, P., Fizazi, Karim
المساهمون: Université de Lille, CHU Lille, Institut Bergonié Bordeaux, Centre Régional de Lutte contre le Cancer Oscar Lambret Lille UNICANCER/Lille, METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694, Institut Paoli-Calmettes IPC, Centre Hospitalier Régional Universitaire de Besançon CHRU Besançon, Institut Gustave Roussy IGR
مصطلحات موضوعية: PROfound, Metastatic castration-resistant prostate, cancer, Olaparib, Safety, Adverse-event management
وصف الملف: application/octet-stream; application/rdf+xml; charset=utf-8; application/pdf
العلاقة: European Journal of Cancer; Eur J Cancer; http://hdl.handle.net/20.500.12210/90084Test
-
2دورية أكاديمية
المؤلفون: Birgersson, M, Chi, MN, Miller, C, Brzozowski, JS, Brown, J, Schofield, L, Taylor, OG, Pearsall, EA, Hewitt, J, Gedye, C, Lincz, LF, Skelding, KA
المصدر: Frontiers in oncology. 11:656120
مصطلحات موضوعية: Medicin och hälsovetenskap
-
3دورية أكاديمية
المؤلفون: Conduit, C, Davis, ID, Goh, JC, Kichenadasse, G, Gurney, H, Harris, CA, Pook, D, Krieger, L, Parnis, F, Underhill, C, Adams, D, Roncolato, F, Joshua, A, Ferguson, T, Prithviraj, P, Morris, M, Harrison, M, Begbie, S, Hovey, E, George, M, Liow, EC, Link, EK, McJannett, M, Gedye, C
العلاقة: Conduit, C., Davis, I. D., Goh, J. C., Kichenadasse, G., Gurney, H., Harris, C. A., Pook, D., Krieger, L., Parnis, F., Underhill, C., Adams, D., Roncolato, F., Joshua, A., Ferguson, T., Prithviraj, P., Morris, M., Harrison, M., Begbie, S., Hovey, E. ,. Gedye, C. (2024). A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma. BJU INTERNATIONAL, 133 (S3), pp.57-67. https://doi.org/10.1111/bju.16190Test.; http://hdl.handle.net/11343/339980Test
-
4دورية أكاديمية
المؤلفون: Day, F, Sridharan, S, Lynam, J, Gedye, C, Johnson, C, Fraser, A, Thompson, SR, Michael, M, Leong, T, Roy, A, Kumar, M, van der Westhuizen, A, Quah, GT, Mandaliya, H, Mallesara, G, Sappiatzer, J, Oldmeadow, C, Martin, J
العلاقة: pii: 10.1186/s12885-022-10407-8; Day, F., Sridharan, S., Lynam, J., Gedye, C., Johnson, C., Fraser, A., Thompson, S. R., Michael, M., Leong, T., Roy, A., Kumar, M., van der Westhuizen, A., Quah, G. T., Mandaliya, H., Mallesara, G., Sappiatzer, J., Oldmeadow, C. & Martin, J. (2022). Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: a single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trials Group). BMC CANCER, 22 (1), https://doi.org/10.1186/s12885-022-10407-8Test.; http://hdl.handle.net/11343/334765Test
-
5دورية أكاديمية
المؤلفون: Pathmanandavel, S, Crumbaker, M, Yam, AO, Nguyen, A, Rofe, C, Hovey, E, Gedye, C, Kwan, EM, Hauser, C, Azad, AA, Eu, P, Martin, AJ, Joshua, AM, Emmett, L
العلاقة: pii: jnumed.121.262552; Pathmanandavel, S., Crumbaker, M., Yam, A. O., Nguyen, A., Rofe, C., Hovey, E., Gedye, C., Kwan, E. M., Hauser, C., Azad, A. A., Eu, P., Martin, A. J., Joshua, A. M. & Emmett, L. (2022). 177 Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN) Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial. JOURNAL OF NUCLEAR MEDICINE, 63 (4), pp.560-566. https://doi.org/10.2967/jnumed.121.262552Test.; http://hdl.handle.net/11343/304962Test
-
6دورية أكاديمية
المؤلفون: Khushalani, N.I., Shue, H., Gedye, C., Mazumder, A., Sharma, S., Eastgate, M., Majem Tarruella, M., Antonanzas Basa, M., Montaudie, H., Marais-Nieman, R., de la Cruz Merino, L., Clements, A., Mortier, L., Jameson, M., Shojaei, F., Ning, J., Aiyer, L., Gillings, M., Kabbinavar, F., Ascierto, P.
المصدر: Annals of Oncology ; volume 33, page S1444 ; ISSN 0923-7534
مصطلحات موضوعية: Oncology, Hematology
الإتاحة: https://doi.org/10.1016/j.annonc.2022.10.052Test
https://api.elsevier.com/content/article/PII:S0923753422042430?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753422042430?httpAccept=text/plainTest -
7دورية أكاديمية
المؤلفون: Albiges, L., Gurney, H.P., Atduev, V., Suárez, C., Climent Duran, M.A., Pook, D., Tomczak, P., Barthelemy, P., Lee, J-L., Nalbandian, T., Stus, V., Ferguson, T., Wiechno, P., Gokmen, E., Lacombe, L., Gedye, C., Perini, R., Sharma, M., C. Li, Lee, C-H.
المصدر: Annals of Oncology ; volume 33, page S1204-S1205 ; ISSN 0923-7534
مصطلحات موضوعية: Oncology, Hematology
الإتاحة: https://doi.org/10.1016/j.annonc.2022.07.1551Test
https://api.elsevier.com/content/article/PII:S0923753422034020?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753422034020?httpAccept=text/plainTest -
8دورية أكاديمية
المؤلفون: Armstrong, A.J., Saad, F., Thiery-Vuillemin, A., Oya, M., Shore, N.D., Mehra, N., Ozguroglu, M., Gedye, C., Sartor, O., Poehlein, C.H., Qiu, P., Liu, Y-Z., Riva, L., Harrington, L., Barker, L., Del Rosario, P.M.D., Barnicle, A., Clarke, N.
المصدر: Annals of Oncology ; volume 33, page S1168 ; ISSN 0923-7534
مصطلحات موضوعية: Oncology, Hematology
الإتاحة: https://doi.org/10.1016/j.annonc.2022.07.1502Test
https://api.elsevier.com/content/article/PII:S0923753422033531?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753422033531?httpAccept=text/plainTest -
9دورية أكاديمية
المؤلفون: Khasraw, M, Weller, M, Lorente, D, Kolibaba, K, Lee, CK, Gedye, C, I de La Fuente, M, Vicente, D, Reardon, DA, Gan, HK, Scott, AM, Dussault, I, Helwig, C, Ojalvo, LS, Gourmelon, C, Groves, M
العلاقة: pii: vdab058; Khasraw, M., Weller, M., Lorente, D., Kolibaba, K., Lee, C. K., Gedye, C., I de La Fuente, M., Vicente, D., Reardon, D. A., Gan, H. K., Scott, A. M., Dussault, I., Helwig, C., Ojalvo, L. S., Gourmelon, C. & Groves, M. (2021). Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma. Neurooncol Adv, 3 (1), pp.vdab058-. https://doi.org/10.1093/noajnl/vdab058Test.; http://hdl.handle.net/11343/304758Test
-
10مؤتمر
المؤلفون: Thiery-Vuillemin, A., Saad, F., Armstrong, A. J., Oya, M., Vianna, K., Özgüroglu, M., Gedye, C., Buchschacher, G. L., Lee, J. Y., Emmenegger, U., Navratil, J., Virizuela, J., Salazar, A., Maillet, D., Uemura, H., Hosius, C., De Champlain, A., Barker, L., Degboe, A. N., Clarke, Noel W
المساهمون: CHRU Besançon Hôpital J.Minjoz, Besançon, France
العلاقة: https://dx.doi.org/10.1200/JCO.2023.41.16_suppl.5012Test; Thiery-Vuillemin A, Saad F, Armstrong AJ, Oya M, Vianna K, Özgüroglu M, et al. Health-related quality of life (HRQoL) and pain outcomes for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received abiraterone (abi) and olaparib (ola) versus (vs) abi and placebo (pbo) in the phase III PROpel trial. Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772001099.; http://hdl.handle.net/10541/626642Test; Journal of Clinical Oncology
الإتاحة: https://doi.org/10.1200/JCO.2023.41.16_suppl.5012Test
http://hdl.handle.net/10541/626642Test
النص الكامل